蓝星安迪苏股份有限公司 关于开展外汇套期保值业务的公告 证券代码：600299 证券简称：安迪苏 公告编号： 2025-023 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要提示： 公司于 2025 年 4 月 28 日召开第九届董事会第六次会议，审议通过了《关 于开展外汇套期保值业务的议案》，同意公司及下属公司开展外汇套期保值业务。 现将情况公告如下： 一、交易情况概述 (一) 交易目的 公司及下属公司的主要经营活动范围位于法国、西班牙、美国和中国等， 主要交易货币为欧元、美元及人民币，日常经营过程中涉及大量贸易项下外汇 资金收付的外币业务。为有效规避和防范外汇市场风险，防止汇率大幅波动对 公司生产经营造成不利影响，公司持续监控汇率风险，并拟结合衍生金融工具 的使用，开展外汇套期保值业务。公司将以真实的业务为基础开展相关外汇套 期保值业务，不进行投机和套利交易。 (二) 交易金额 公司及下属公司根据生产经营情况，拟开展外汇套期保值业务，在授权额 度使用期限内的任一时间点，外汇套期保值业务规模均不超过 10 亿欧元。额度 ...

1 可持续发展报告 2024 www.adisseo.com 本文件由安迪苏发布，旨在帮助利益相关方全面了解 安迪苏在实现可持续发展目标过程中，在环境、社会 和治理领域所做的贡献、采取的行动及取得的成果。 报告主体和缩写术语 蓝星安迪苏股份有限公司。 为便于表述，将以"安迪苏" 、"公司"或"我们/我们的"表示。 安迪苏的母公司"中 国蓝星（集团）股份有限公司"简称为"中国蓝星 "。 (2-1) 报告范围 本报告涵盖2024年1月1日至2024年12月31日期间， 公司合并财务报表范围内的所有全球子公司。 您可 以在我们的2024年度报告中查看子公司清单。 (2-2) 安迪苏是《责任关怀全球宪章》 的签署者，致力于在产品的全生 命周期内进行安全管理，推动产 品在提升生活质量方面的积极 作用，并强化其对可持续发展的 贡献。 联系我们 蓝星安迪苏股份有限公司 地址：北京市朝阳区北土城西路9号 电话：+86 10 61958802 邮箱：InvestorService@adisseo.com 关于报告 报告期与频率 我们的报告期为2024年1月1日至2024年12月31日， 与公司财务报告的期间一致。 为了保持信息 ...

Core Insights - As of April 21, 2024, 2,246 companies have released their annual reports, with 1,197 reporting a year-on-year increase in net profit, while 1,049 reported a decline [1] - A total of 1,341 companies saw an increase in operating revenue, whereas 904 experienced a decrease [1] - Companies that reported simultaneous growth in both net profit and operating revenue include 940 firms, while 648 companies saw declines in both metrics [1] - Notably, 234 companies achieved a net profit growth rate exceeding 100%, with Zhengdan Co., Ltd. leading at an impressive 11,949.39% increase [1] Company Performance Summary - Zhengdan Co., Ltd. (300641) reported earnings per share of 2.35 yuan, with a net profit of 1,189.89 million yuan, reflecting a year-on-year increase of 11,949.39%, and operating revenue of 348.02 million yuan, up 126.31% [1] - Guangxi Energy (600310) reported earnings per share of 0.043 yuan, with a net profit of 62.99 million yuan, a significant increase of 3,704.04%, but a decline in operating revenue by 76.48% to 393.16 million yuan [1] - Siwei (688213) achieved earnings per share of 0.98 yuan, with a net profit of 39.27 million yuan, marking a 2,662.76% increase, and operating revenue of 596.81 million yuan, up 108.87% [1] - Other notable performers include Andis (600299) with a net profit of 120.43 million yuan (up 2,208.66%) and operating revenue of 1,553.43 million yuan (up 17.83%) [1] - Companies like Huabei Pharmaceutical (600812) and Jiangsu Suo (600746) also reported significant changes in their financial metrics, with varying trends in net profit and operating revenue [1][2]

Core Viewpoint - The company, Andisu, is undergoing significant capital operations, marking its largest since its reverse merger in 2015, with a focus on expanding its production capacity in the animal nutrition sector [1] Group 1: Company Overview - Andisu specializes in the research, production, and sales of animal nutrition additives, holding a leading position in the industry for several core products [3] - The company's product offerings are categorized into functional products, such as methionine and vitamins, and specialty products aimed at enhancing animal health and feed efficiency [3] Group 2: Investment Projects - The company plans to invest CNY 1.743 billion (approximately USD 246 million) in a solid methionine project with an annual capacity of 150,000 tons, accounting for 46.3% of the total fundraising amount [4] - The project will be located in Quanzhou, Fujian Province, and is expected to commence production in 2027 [4] - The liquid methionine production capacity at Andisu's Nanjing plant is currently the second largest globally, which will create synergies with the new solid methionine expansion [4] Group 3: Financial Performance - In 2024, Andisu is projected to achieve a revenue of CNY 15.53 billion (approximately USD 2.23 billion), representing a year-on-year growth of 17.83% [9] - The net profit attributable to shareholders is expected to reach CNY 1.204 billion (approximately USD 171 million), showing a dramatic increase of 2215% compared to 2023, although this is largely due to a low base effect from the previous year [9] - The company's net profit in 2023 was only CNY 52 million (approximately USD 7.4 million), a decline of nearly 96% from CNY 1.247 billion (approximately USD 178 million) in 2022 [9] Group 4: Market Dynamics - The methionine market is dominated by international giants, with a global market size projected to exceed 1.5 million tons by 2028, while the current domestic production rate is below 30% [3] - The industry has experienced a cyclical nature, with methionine prices significantly influenced by global capacity expansions, leading to an oversupply situation [10] - From 2016 to 2023, the average price of methionine in the domestic market decreased by 34% [10] Group 5: Cost and Profitability - The company's operating costs have risen sharply from CNY 7.465 billion (approximately USD 1.06 billion) in 2016 to CNY 13.669 billion (approximately USD 1.96 billion) in 2024 [12] - Despite efforts to optimize supply chain management, the pressure from rising costs, driven by high prices of key raw materials and global supply chain disruptions, has significantly impacted profitability [12] - The gross margin has decreased from 47.43% in 2016 to 21.38% in 2023, with a recovery to 30.21% anticipated in 2024 [10]

星标 ★ IPO日报 精彩文章第一时间推送 近期，全球动物营养添加剂龙头蓝星安迪苏股份有限公司（600299.SH，下称"安迪苏"）发布公告，公司拟向特定对象发行预计发行数量不超过8 亿股公司股票，募集资金总额不超过30亿元，用于四大核心项目及补充流动资金。 4月16日，该事项获上交所受理。 不过，作为动物必需氨基酸，蛋氨酸市场长期被赢创、住友、诺伟司等国际巨头垄断。兴业证券研报显示，全球蛋氨酸市场规模预计2028年将突破 150万吨，当前国产化率不足30%。 在此次募投项目中，公司拟使用17.43亿元，投入年产能为15万吨的固体蛋氨酸项目，占总募资额的46.3%，进一步扩产。该项目实施地点在福建 省泉州市，预计于2027年投产。 值得关注的是，安迪苏南京工厂的液体蛋氨酸产能已达全球第二，与此次固体蛋氨酸的扩产将形成协同效应。 这是继2015年通过反向收购重组上市后，公司规模最大的资本运作。 制图：佘诗婕 发挥协同效应 据悉，安迪苏主要从事动物营养添加剂的研发、生产及销售。公司在动物饲料添加剂领域中，多个核心产品的产业规模与技术水平处于行业领先地 位。 具体来看，公司产品主要分为两类，包括功能性产品和特种产品 ...

Core Viewpoint - The company, Andisu, is progressing with its private placement fundraising project, aiming to raise up to 3 billion yuan for various strategic initiatives, including functional and specialty product projects, sustainable development, and working capital [1][2]. Group 1: Fundraising and Strategic Development - The private placement aims to raise a total of no more than 3 billion yuan, with net proceeds allocated to functional products, specialty products, sustainable development projects, and working capital [2][3]. - The company has categorized its main business products into functional products, which include methionine, vitamins, and ammonium sulfate, and specialty products, which focus on enhancing animal health and feed quality [2][3]. Group 2: Financial Performance and Recovery - After experiencing a significant decline in performance in 2022 and 2023, the company is expected to return to normal operations in 2024, with projected revenues of 15.534 billion yuan and a net profit of 1.204 billion yuan [1][6]. - The company reported a 24% increase in revenue from functional products in 2024, achieving 11.622 billion yuan, while specialty products generated 3.913 billion yuan, reflecting a 4% growth [2][5]. - The company’s net profit for 2024 is projected to increase by 2208.66% compared to the previous year, indicating a strong recovery [6]. Group 3: Market Position and Growth - The company has increased its market share in methionine from 23% in 2012 to 28% in 2023, solidifying its leadership position in the industry [5]. - The company is expanding its global market presence, with double-digit sales growth in Europe, North America, and Asia in 2024 [3]. - The price of methionine has risen by approximately 8.14% since 2025, which is expected to positively impact the company's performance [3].

Core Insights - As of April 17, 1695 companies have released their 2024 annual reports, with 947 reporting a year-on-year increase in net profit, while 748 reported a decline [1] - 1026 companies saw a year-on-year increase in operating revenue, whereas 669 experienced a decrease [1] - 750 companies reported simultaneous growth in both net profit and operating revenue, while 472 companies saw declines in both metrics [1] - A total of 180 companies achieved a doubling of their performance, with Zhengdan Co. leading with a staggering net profit growth of 11949.39% [1] Company Performance Summary - Zhengdan Co. (300641) reported earnings per share of 2.35 yuan, net profit of 118.99 million yuan, a year-on-year increase of 11949.39%, and operating revenue of 348.02 million yuan, up 126.31% [1] - Guangxi Energy (600310) had earnings per share of 0.043 yuan, net profit of 6.30 million yuan, a year-on-year increase of 3704.04%, but a significant decline in operating revenue by 76.48% to 393.16 million yuan [1] - North China Pharmaceutical (600812) reported earnings per share of 0.074 yuan, net profit of 12.70 million yuan, a year-on-year increase of 2496.80%, with operating revenue of 986.96 million yuan, down 2.48% [1] - Andisoo (600299) achieved earnings per share of 0.45 yuan, net profit of 120.43 million yuan, a year-on-year increase of 2208.66%, and operating revenue of 1.55 billion yuan, up 17.83% [1] - Other notable companies include Jiangsu Suopu (600746) with a net profit increase of 1029.62% and operating revenue growth of 18.43% [1] Additional Company Insights - Baoli Tianheng (688506) reported an impressive earnings per share of 9.25 yuan, net profit of 370.75 million yuan, and a remarkable year-on-year increase of 936.31% in net profit, with operating revenue of 582.27 million yuan [2] - Muyuan Foods (002714) achieved earnings per share of 3.30 yuan, net profit of 1.79 billion yuan, a year-on-year increase of 519.42%, and operating revenue of 13.79 billion yuan, up 24.43% [2] - Other companies like Xizi Clean Energy (002534) and Zhongchuan Defense (600685) reported varying performance metrics, with Xizi Clean Energy showing a decline in operating revenue by 20.33% [2]

证券代码：600299 证券简称：安迪苏 公告编号：2025-020 蓝星安迪苏股份有限公司 关于公司向特定对象发行 A 股股票申请 获得上海证券交易所受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特此公告。 蓝星安迪苏股份有限公司董事会 2025 年 4 月 16 日 蓝星安迪苏股份有限公司（以下简称"公司"）于 2025 年 4 月 15 日收到上海证券交 易所出具的《关于受理蓝星安迪苏股份有限公司沪市主板上市公司发行证券申请的通 知》（上证上审（再融资）〔2025〕101 号）。上海证券交易所依据相关规定对公司报 送的沪市主板上市公司发行证券的募集说明书及相关申请文件进行了核对，认为该项 申请文件齐备，符合法定形式，决定予以受理并依法进行审核。 公司向特定对象发行 A 股股票事项尚需上海证券交易所审核通过，并获得中国证 券监督管理委员会同意注册后方可实施。最终能否通过上海证券交易所审核，并获得 中国证券监督管理委员会同意注册的决定及其时间尚存在不确定性。公司将根据进展 情况，严格按照上市公司向特定对象发行股 ...

蓝星安迪苏股份有限公司 向特定对象发行 A 股股票 募集说明书 （申报稿） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期） 北座 股票简称：安迪苏 股票代码：600299 保荐人（主承销商） 二〇二五年四月 蓝星安迪苏股份有限公司 向特定对象发行 A 股股票募集说明书（申报稿） 声 明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露 资料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及 完整性承担连带赔偿责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财 务会计资料真实、完整。 中国证券监督管理委员会、上海证券交易所对本次发行所作的任何决定或 意见，均不表明其对申请文件及所披露信息的真实性、准确性、完整性作出保 证，也不表明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质 性判断或保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由 发行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资 风险。 1- ...

北京市金杜律师事务所 关于蓝星安迪苏股份有限公司 向特定对象发行 A 股股票的法律意见书 致：蓝星安迪苏股份有限公司 北京市金杜律师事务所（以下简称"本所"）接受蓝星安迪苏股份有限公司（以 下简称"发行人"）委托，担任发行人向特定对象发行 A 股股票（以下简称"本次 发行"）的专项法律顾问。 本所根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司证券发行注册管理办法》（以 下简称"《注册管理办法》"）、《律师事务所从事证券法律业务管理办法》（以下 简称《" 证券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》 （以下简称"《证券法律业务执业规则》"）、《公开发行证券公司信息披露的编报 规则第 12 号－－公开发行证券的法律意见书和律师工作报告》等中华人民共和 国境内（以下简称"中国境内"，为本法律意见书之目的，不包括中国香港特别行 政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、部门 规章和规范性文件和中国证券监督管理委员会（以下简称"中国证监会"）、上海 证券交易所（以下简称"上交所"）的有关规定，按照 ...